hydroxyurea has been researched along with Hypercoagulability in 34 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 8.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| "Hydroxyurea is an old drug that is often used to control essential thrombocythemia and polycythemia vera in patients with high-risk disease." | 4.83 | Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia. ( Dingli, D; Tefferi, A, 2006) |
| "Secondary thrombocytosis is a frequent secondary finding in childhood infection and inflammation." | 2.72 | Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management. ( Cario, H; Duffert, CM; Knöfler, R; Kulozik, AE; Stockklausner, C; Streif, W, 2021) |
| "Essential thrombocythemia is a chronic myeloproliferative neoplasm characterized by sustained thrombocytosis, bone marrow megakaryocytic hyperplasia and an increased risk of thrombosis and hemorrhage." | 2.49 | [Treatment of essential thrombocythemia]. ( Alvarez-Larrán, A; Besses, C; Cervantes, F, 2013) |
| "Treatment with busulfan or interferon-α is usually effective in hydroxyurea failures." | 2.48 | Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management. ( Tefferi, A, 2012) |
| "Venous thrombosis is more frequent in PV than in ET; superficial or deep venous thromboses are seen." | 2.41 | [What vascular events suggest a myeloproliferative disorder?]. ( Caulier-Leleu, MT; Hachulla, E; Pasturel-Michon, U; Rose, C; Trillot, N, 2000) |
| "Clinical severity of thalassemia intermedia increases with age, with more severe anemia and more frequent complications such as extramedullary hematopoiesis and iron overload mainly related to increased intestinal absorption." | 1.40 | [Current management of thalassemia intermedia]. ( Thuret, I, 2014) |
| "Treatment with hydroxyurea, in addition to the regulation of haemolysis, lowers Ed-MPs and attenuates thrombin generation." | 1.38 | The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles. ( Blanc-Brude, O; Chaari, M; Elalamy, I; Galea, V; Gerotziafas, GT; Girot, R; Hatmi, M; Khaterchi, A; Lionnet, F; Maier-Redelsperger, M; Stankovic-Stojanovic, K; Van Dreden, P; Woodhams, B, 2012) |
| "Mechanical valve thrombosis is a rare condition in an adequately anticoagulated patient in the absence of underlying thrombophilia." | 1.37 | Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report. ( Cherian, SV; Das, S; Gajra, A; Garcha, AS; Jasti, S; Karachiwala, H, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (5.88) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 15 (44.12) | 24.3611 |
| 2020's | 2 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Bewersdorf, JP | 1 |
| Zeidan, AM | 1 |
| Stockklausner, C | 1 |
| Duffert, CM | 1 |
| Cario, H | 1 |
| Knöfler, R | 1 |
| Streif, W | 1 |
| Kulozik, AE | 1 |
| Alvarez-Larrán, A | 1 |
| Cervantes, F | 1 |
| Besses, C | 2 |
| Fu, R | 1 |
| Zhang, L | 1 |
| Yang, R | 1 |
| Stein, BL | 1 |
| Moliterno, AR | 1 |
| Tiu, RV | 1 |
| Thuret, I | 1 |
| Kreher, S | 1 |
| Ochsenreither, S | 1 |
| Trappe, RU | 1 |
| Pabinger, I | 1 |
| Bergmann, F | 1 |
| Petrides, PE | 1 |
| Koschmieder, S | 1 |
| Matzdorff, A | 1 |
| Tiede, A | 1 |
| Griesshammer, M | 1 |
| Riess, H | 1 |
| Lim, Y | 1 |
| Lee, JO | 1 |
| Kim, SH | 1 |
| Kim, JW | 1 |
| Kim, YJ | 1 |
| Lee, KW | 1 |
| Lee, JS | 1 |
| Bang, SM | 1 |
| Fourgeaud, C | 1 |
| El Nemer, W | 1 |
| Michon Pasturel, U | 1 |
| Bonhomme, S | 1 |
| Brignier, A | 1 |
| Lazareth, I | 1 |
| Priollet, P | 1 |
| Hernández-Boluda, JC | 1 |
| Pérez Encinas, M | 1 |
| Raya, JM | 1 |
| Hernández-Rivas, JM | 1 |
| Jiménez Velasco, A | 1 |
| Martínez Lopez, J | 1 |
| Vicente, V | 1 |
| Burgaleta, C | 1 |
| Spanoudakis, E | 1 |
| Bazdiara, I | 1 |
| Kotsianidis, I | 1 |
| Margaritis, D | 1 |
| Goutzouvelidis, A | 1 |
| Christoforidou, A | 1 |
| Tsatalas, C | 1 |
| Bourikas, G | 1 |
| Allegra, A | 1 |
| Alonci, A | 1 |
| Penna, G | 1 |
| D'Angelo, A | 1 |
| Rizzotti, P | 1 |
| Granata, A | 1 |
| Musolino, C | 1 |
| Kurosawa, H | 1 |
| Okuya, M | 1 |
| Matsushita, T | 1 |
| Kubota, T | 1 |
| Endoh, K | 1 |
| Kuwashima, S | 1 |
| Hagisawa, S | 1 |
| Sato, Y | 1 |
| Fukushima, K | 1 |
| Sugita, K | 1 |
| Okada, Y | 1 |
| Park, MJ | 1 |
| Hayashi, Y | 1 |
| Arisaka, O | 1 |
| Beer, PA | 1 |
| Green, AR | 3 |
| Dingli, D | 1 |
| Tefferi, A | 2 |
| Weston, H | 1 |
| Cowell, V | 1 |
| Grimmett, K | 1 |
| Saal, R | 1 |
| Jones, M | 1 |
| Mills, T | 1 |
| Gill, D | 1 |
| Marlton, P | 1 |
| Bird, R | 1 |
| Mollee, P | 1 |
| Panova-Noeva, M | 1 |
| Marchetti, M | 2 |
| Buoro, S | 1 |
| Russo, L | 1 |
| Leuzzi, A | 1 |
| Finazzi, G | 3 |
| Rambaldi, A | 1 |
| Ottomano, C | 1 |
| Ten Cate, H | 1 |
| Falanga, A | 1 |
| Das, S | 1 |
| Karachiwala, H | 1 |
| Cherian, SV | 1 |
| Garcha, AS | 1 |
| Jasti, S | 1 |
| Gajra, A | 1 |
| Aygun, B | 1 |
| Wruck, LM | 1 |
| Schultz, WH | 1 |
| Mueller, BU | 1 |
| Brown, C | 1 |
| Luchtman-Jones, L | 1 |
| Jackson, S | 1 |
| Iyer, R | 1 |
| Rogers, ZR | 1 |
| Sarnaik, S | 1 |
| Thompson, AA | 1 |
| Gauger, C | 1 |
| Helms, RW | 1 |
| Ware, RE | 1 |
| Gerotziafas, GT | 1 |
| Van Dreden, P | 1 |
| Chaari, M | 1 |
| Galea, V | 1 |
| Khaterchi, A | 1 |
| Lionnet, F | 1 |
| Stankovic-Stojanovic, K | 1 |
| Blanc-Brude, O | 1 |
| Woodhams, B | 1 |
| Maier-Redelsperger, M | 1 |
| Girot, R | 1 |
| Hatmi, M | 1 |
| Elalamy, I | 1 |
| Garrido, VT | 1 |
| Proença-Ferreira, R | 1 |
| Dominical, VM | 1 |
| Traina, F | 1 |
| Bezerra, MA | 1 |
| de Mello, MR | 1 |
| Colella, MP | 1 |
| Araújo, AS | 1 |
| Saad, ST | 1 |
| Costa, FF | 1 |
| Conran, N | 1 |
| Al-Zahrani, H | 1 |
| Gupta, V | 1 |
| Minden, MD | 1 |
| Messner, HA | 1 |
| Lipton, JH | 1 |
| Ruggeri, M | 1 |
| Rodeghiero, F | 2 |
| Barbui, T | 3 |
| Kornblihtt, LI | 1 |
| Heller, PG | 1 |
| Correa, G | 1 |
| Castañón, M | 1 |
| Genoud, V | 1 |
| Vassallu, P | 1 |
| Sarano, J | 1 |
| Kordich, L | 1 |
| Molinas, FC | 1 |
| Barosi, G | 1 |
| Grossi, A | 1 |
| Gugliotta, L | 1 |
| Liberato, LN | 1 |
| Mazzucconi, MG | 1 |
| Tura, S | 1 |
| Vassiliou, GS | 1 |
| Curtin, N | 1 |
| Campbell, PJ | 1 |
| Landolfi, R | 1 |
| Di Gennaro, L | 1 |
| van Genderen, PJ | 1 |
| Leenknegt, H | 1 |
| Michiels, JJ | 1 |
| Hachulla, E | 1 |
| Rose, C | 2 |
| Trillot, N | 1 |
| Caulier-Leleu, MT | 1 |
| Pasturel-Michon, U | 1 |
| Briere, J | 1 |
| Guilmin, F | 1 |
| Gyan, E | 1 |
| Darre, S | 1 |
| Jude, B | 1 |
| Cambier, N | 1 |
| Demory, JL | 1 |
| Bauters, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prospective Clinical Study on Early Inflammatory, Cell Adhesion and Hemostatic Plasmatic Markers of Endothelial Dysfunction in Children With Sickle Cell Disease (SCD)[NCT04839159] | 41 participants (Anticipated) | Interventional | 2012-05-10 | Active, not recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
16 reviews available for hydroxyurea and Hypercoagulability
| Article | Year |
|---|---|
Novel and combination therapies for polycythemia vera and essential thrombocythemia: the dawn of a new era.
Topics: Bone Marrow; Clinical Trials as Topic; Combined Modality Therapy; DNA Methylation; Drugs, Investigat | 2020 |
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Topics: Adolescent; Adult; Age of Onset; Algorithms; Anticoagulants; Calreticulin; Child; Disease Management | 2021 |
[Treatment of essential thrombocythemia].
Topics: Adult; Age Factors; Aged; Anticoagulants; Aspirin; Cell Transformation, Neoplastic; Disease Progress | 2013 |
Paediatric essential thrombocythaemia: clinical and molecular features, diagnosis and treatment.
Topics: Adolescent; Age of Onset; Anticoagulants; Child; Child, Preschool; Clone Cells; Disease Progression; | 2013 |
Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options.
Topics: Clinical Trials, Phase III as Topic; Combined Modality Therapy; Cost of Illness; Disease Progression | 2014 |
[Vascular myeloproliferative neoplasm with normal cell blood count: Exploration and medical management].
Topics: Aged; Blood Cell Count; Bone Marrow; Cell Adhesion; Cell Adhesion Molecules; Comorbidity; Diagnosis, | 2015 |
Pathogenesis and management of essential thrombocythemia.
Topics: Acute Disease; Aged; Aspirin; Clone Cells; Disease Management; Disease Progression; Humans; Hydroxyu | 2009 |
Hydroxyurea: The drug of choice for polycythemia vera and essential thrombocythemia.
Topics: Aged; Agranulocytosis; Alkylating Agents; Clinical Trials as Topic; Combined Modality Therapy; Disea | 2006 |
Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Topics: Acute Disease; Age Factors; Alkylating Agents; Anticoagulants; Aspirin; Busulfan; Disease Management | 2012 |
Vascular events associated with alpha interferon therapy.
Topics: Adult; Antineoplastic Agents; Fatal Outcome; Female; Foot Ulcer; Gangrene; Hemolytic-Uremic Syndrome | 2003 |
Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.
Topics: Acute Disease; Adult; Aged; Alkylating Agents; Cell Transformation, Neoplastic; Child; Clinical Tria | 2004 |
Management of the myeloproliferative disorders : distinguishing data from dogma.
Topics: Abnormalities, Drug-Induced; Adult; Aged; Anticoagulants; Contraindications; Female; Humans; Hydroxy | 2004 |
The pathogenesis and management of essential thrombocythaemia.
Topics: Acute Disease; Alkylating Agents; Aspirin; Cardiovascular Diseases; Clone Cells; Gene Expression; He | 1999 |
[What vascular events suggest a myeloproliferative disorder?].
Topics: Adult; Aged; Alkylating Agents; Arterial Occlusive Diseases; Cross-Sectional Studies; Erythromelalgi | 2000 |
Efficacy and safety of hydroxyurea in patients with essential thrombocythemia.
Topics: Adult; Aged; Aged, 80 and over; Anemia; Cell Transformation, Neoplastic; Cohort Studies; Female; Fol | 2001 |
Management of patients with essential thrombocythemia: current concepts and perspectives.
Topics: Adult; Aged; Aspirin; Case Management; Clinical Trials as Topic; Diagnosis, Differential; Disease Pr | 2001 |
2 trials available for hydroxyurea and Hypercoagulability
| Article | Year |
|---|---|
Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients.
Topics: Bone Marrow; Clone Cells; Hematopoietic Stem Cells; Humans; Hydroxyurea; Janus Kinase 2; Mutation, M | 2009 |
Chronic transfusion practices for prevention of primary stroke in children with sickle cell anemia and abnormal TCD velocities.
Topics: Anemia, Sickle Cell; Autoantibodies; Blood Flow Velocity; Cerebrovascular Circulation; Child; Child, | 2012 |
16 other studies available for hydroxyurea and Hypercoagulability
| Article | Year |
|---|---|
[Current management of thalassemia intermedia].
Topics: Allografts; alpha-Thalassemia; beta-Thalassemia; Blood Transfusion; Chelation Therapy; Combined Moda | 2014 |
Prophylaxis and management of venous thromboembolism in patients with myeloproliferative neoplasms: consensus statement of the Haemostasis Working Party of the German Society of Hematology and Oncology (DGHO), the Austrian Society of Hematology and Oncolo
Topics: Anticoagulants; Disease Susceptibility; Drug Interactions; Female; Hemorrhage; Heparin, Low-Molecula | 2014 |
Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Blood Cell Count; Comorbidity; Databases, Factual; | 2015 |
Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method.
Topics: Bone Marrow Examination; Delphi Technique; Diagnosis, Differential; Disease Management; DNA Mutation | 2016 |
JAK2 V617F-positive latent essential thrombocythemia and splanchnic vein thrombosis: the role of bone marrow biopsy for the diagnosis of myeloproliferative disease.
Topics: Abdominal Pain; Acenocoumarol; Adult; Anticoagulants; Biopsy; Bone Marrow; Bone Marrow Examination; | 2009 |
JAK2V617F mutation-positive childhood essential thrombocythemia associated with cerebral venous sinus thrombosis.
Topics: Aspirin; Child; Clone Cells; Cytotoxins; Diagnosis, Differential; Female; Headache; Humans; Hydroxyu | 2009 |
Prognostic utility of spontaneous erythroid colony formation and JAK2 mutational analysis for thrombotic events in essential thrombocythaemia.
Topics: Adult; Aged; Aged, 80 and over; Colony-Forming Units Assay; DNA Mutational Analysis; Erythroid Precu | 2011 |
JAK2V617F mutation and hydroxyurea treatment as determinants of immature platelet parameters in essential thrombocythemia and polycythemia vera patients.
Topics: Blood Platelets; Humans; Hydroxyurea; Janus Kinase 2; Mutation, Missense; Phenotype; Platelet Count; | 2011 |
Anticoagulant-resistant thrombophilia in a patient with polycythemia vera: a case report.
Topics: Aged; Anticoagulants; Aspirin; Factor Xa; Factor Xa Inhibitors; Fatal Outcome; Heparin, Low-Molecula | 2011 |
The acceleration of the propagation phase of thrombin generation in patients with steady-state sickle cell disease is associated with circulating erythrocyte-derived microparticles.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; Blood Coagulation; Blood Coagulation Te | 2012 |
Elevated plasma levels and platelet-associated expression of the pro-thrombotic and pro-inflammatory protein, TNFSF14 (LIGHT), in sickle cell disease.
Topics: Adolescent; Adult; Anemia, Sickle Cell; Biomarkers; Blood Platelets; Endothelium, Vascular; Female; | 2012 |
Efficacy and safety of long-term use of hydroxyurea in young patients with essential thrombocythemia and a high risk of thrombosis.
Topics: Adolescent; Adult; Anemia; Cohort Studies; Follow-Up Studies; Hemorrhage; Humans; Hydroxyurea; Incid | 2003 |
Associated thrombophilic defects in essential thrombocythaemia: their relationship with clinical manifestations.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amino Acid Substitution; Antithrombin III; Child; Female | 2003 |
Prevention of thrombosis in polycythemia vera and essential thrombocythemia.
Topics: Arterial Occlusive Diseases; Aspirin; Clopidogrel; Dipyridamole; Drug Therapy, Combination; Humans; | 2008 |
The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
Topics: Aged; Alkylating Agents; Aspirin; Erythromelalgia; Female; Fibrinolytic Agents; Hemorrhage; Hemorrha | 1997 |
Acute priapism in a patient with unstable hemoglobin Perth and Factor V Leiden under effective oral anticoagulant therapy.
Topics: Activated Protein C Resistance; Adult; Anticoagulants; Cell Adhesion; Erythrocyte Membrane; Etilefri | 2001 |